Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Ionis Pharmaceuticals earns milestone from Bayer for advancing antisense drugs

Feb. 15, 2017

Anti-VEGF-B agent CSL-346 developed to treat diabetic kidney disease

Feb. 14, 2017

First patient dosed in Angion Biomedica's phase II study of BB3

Feb. 1, 2017

Lundbeck discovers novel PDE9 inhibitors

Jan. 26, 2017

Resverlogix reports results from phase I trial of apabetalone in severe kidney impairment

Jan. 24, 2017

Roche divulges novel DDR1 inhibitors

Jan. 20, 2017

Chongqing University reports PDE5A inhibitors

Jan. 13, 2017

Kissei Pharmaceutical describes TRPM8 antagonists

Jan. 12, 2017

Phase IIa study of SER-150 in diabetic nephropathy reaches primary endpoint

Jan. 5, 2017

Ardelyx initiates two new trials of RDX-7675 for hyperkalemia

Jan. 5, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...